Asunto(s)
Cannabis , Abuso de Marihuana , Analgésicos , Países Desarrollados , Femenino , Humanos , Embarazo , PrevalenciaRESUMEN
Essentials Low-molecular-weight heparin (LMWH) is used to prevent venous thromboembolism (VTE) in pregnancy. We evaluated the association between LMWH and large for gestational age (LGA) infants. We found no significant associations between LMWH use and LGA. LMWH does not appear to increase the risk for the delivery of an LGA infant. SUMMARY: Background Low-molecular-weight heparin (LMWH), an anticoagulant, is the recommended drug for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy. During pregnancy, LMWH is routinely prescribed to mothers with an increased risk of VTE or with a history of thrombosis. Although clinical reports of larger offspring born to women administered LMWH have been noted, no studies to date have evaluated or associated the use of LMWH and large for gestational age (LGA) infants. Objectives To determine whether there is an association between LMWH usage in mothers and the prevalence of LGA. Patients/Methods We performed an analysis of the Ottawa and Kingston (OaK) Birth Cohort and report characteristics of LMWH and association LGA (> 10%ile). We used coarsened exact matching (CEM) methods to account for bias and confounding. Results A total of 7519 women from the OaK Birth Cohort were included; 59 were administered LMWH during pregnancy (0.78%). Mothers prescribed LMWH had significantly greater BMI (P = 0.0001), age (P = 0.0001) and parity (P = 0.02). Gestational length was shorter among women administered LMWH compared to those without treatment (37.7 ± 2.0 vs. 39.2 ± 2.0, P < 0.0001), an iatrogenic finding. The odds ratio of an LGA delivery among women administered LMWH was 1.02 (95% confidence interval [CI], 0.48-2.16; P = 0.96) in unadjusted analyses and was 1.15 (95% CI, 0.49-2.71) in the matched sample adjusted for maternal age, BMI and gestational age. Conclusions These results, although exploratory, provide indirect evidence of no increased risk of LGA infants among women prescribed LMWH.
Asunto(s)
Anticoagulantes/efectos adversos , Macrosomía Fetal/inducido químicamente , Heparina de Bajo-Peso-Molecular/efectos adversos , Complicaciones Cardiovasculares del Embarazo/prevención & control , Tromboembolia Venosa/prevención & control , Adulto , Anticoagulantes/administración & dosificación , Femenino , Macrosomía Fetal/diagnóstico , Macrosomía Fetal/epidemiología , Edad Gestacional , Heparina de Bajo-Peso-Molecular/administración & dosificación , Humanos , Ontario/epidemiología , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Complicaciones Cardiovasculares del Embarazo/epidemiología , Prevalencia , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Resultado del Tratamiento , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/epidemiología , Adulto JovenRESUMEN
Essentials Clinical benefit of hospitalization vs. outpatient treatment in pulmonary embolism (PE) is unknown. We performed a propensity matched cohort study of hemodynamically stable PE patients. Regardless of the risk assessment, hospitalized patients had the highest rate of adverse event. If confirmed, ambulatory care of normotensive PE patients may be preferred whenever possible. SUMMARY: Background The decision to hospitalize or not patients with acute pulmonary embolism (PE) is controversial. Despite the advantages of close monitoring, hospitalization by itself may lead to in-hospital complications and potentially worsen the prognosis of PE patients. Objectives To determine the net clinical benefit of hospitalization vs. outpatient management of normotensive patients with acute pulmonary embolism (PE). Methods Retrospective cohort propensity score analysis (radius marching with replacement). Hemodynamically stable PE patients treated as outpatients or inpatients were matched to balance out differences for 28 patient characteristics and known risk factors for adverse events. The primary outcome was the rate of adverse events at 14 days, including recurrent venous thromboembolism, major bleeding or death. Results Among 1127 eligible patients, 1081 were included in the matched cohort, 576 treated as inpatients and 505 as outpatients. The 14-day rate of adverse events was 13.0% for inpatients and 3.3% for outpatients (adjusted OR, 5.07; 95% CI, 1.68-15.28). The 3-month rate was 21.7% for inpatients and 6.9% for outpatients (OR, 4.90; 95% CI, 2.62-9.17). In the high-risk subgroup (Pulmonary Embolism Severity Index class III-V; n = 597), the 14-day rate of adverse events was 16.5% for hospitalized patients vs. 4.5% for outpatients (OR, 4.16; 95% CI, 1.2-14.35). Conclusion Outpatient treatment of hemodynamically stable PE patients seems to be associated with a lower rate of adverse events than hospitalization and, if confirmed, may be considered as first-line management in patients not requiring specific in-hospital care, regardless of their initial risk stratification, if proper outpatient care can be provided.
Asunto(s)
Hospitalización , Pacientes Ambulatorios , Embolia Pulmonar/terapia , Enfermedad Aguda , Adulto , Anciano , Anticoagulantes/uso terapéutico , Femenino , Hemodinámica , Hemorragia/inducido químicamente , Humanos , Pacientes Internos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Perfusión , Pronóstico , Puntaje de Propensión , Arteria Pulmonar/diagnóstico por imagen , Análisis de Regresión , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Resultado del Tratamiento , Ultrasonografía , Tromboembolia Venosa/tratamiento farmacológicoRESUMEN
We describe the relationship between socio-economic status and current bidi or cigarette smoking among Indian men aged ≥15 years. The prevalence of bidi smoking was 13.7% (95%CI 13.3-14.1) and that of cigarette smoking was 6.3% (95%CI 6.1-6.6). bidi smoking was concentrated among the socio-economically disadvantaged, while cigarette smoking was common among men with higher status occupations and greater levels of education and household wealth. This suggests that India has not transitioned to the later stages of the tobacco epidemic, and underscores the need for prevention and control strategies adapted to current patterns of consumption across socio-economic groups in India.